Baxter International Inc. (BIT:1BAX)
Italy flag Italy · Delayed Price · Currency is EUR
24.79
+0.24 (0.98%)
At close: Jul 25, 2025

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Chronic Therapies
-
Log In
Log In
Log In
Log In
Upgrade
Chronic Therapies Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other
-
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade
Medication Delivery
-
Log In
Log In
Log In
Log In
Upgrade
Medication Delivery Growth
-
Log In
Log In
Log In
Log In
Upgrade
Clinical Nutrition
-
Log In
Log In
Log In
Log In
Upgrade
Clinical Nutrition Growth
-
Log In
Log In
Log In
Log In
Upgrade
Advanced Surgery
1.10B
Log In
Log In
Log In
Log In
Upgrade
Advanced Surgery Growth
3.84%
Log In
Log In
Log In
Log In
Upgrade
Pharmaceuticals
-
Log In
Log In
Log In
Log In
Upgrade
Pharmaceuticals Growth
-
Log In
Log In
Log In
Log In
Upgrade
Acute Therapies
-
Log In
Log In
Log In
Log In
Upgrade
Acute Therapies Growth
-
Log In
Log In
Log In
Log In
Upgrade
Patient Support Systems
-
Log In
Log In
Log In
Log In
Upgrade
Patient Support Systems Growth
-
Log In
Log In
Log In
Log In
Upgrade
Surgical Solutions
-
Log In
Log In
Log In
Log In
Upgrade
Surgical Solutions Growth
-
Log In
Log In
Log In
Log In
Upgrade
Front Line Care
1.14B
Log In
Log In
Log In
Log In
Upgrade
Front Line Care Growth
-2.30%
Log In
Log In
Log In
Log In
Upgrade
Injectables and Anesthesia
1.37B
Log In
Log In
Log In
Log In
Upgrade
Injectables and Anesthesia Growth
0.73%
Log In
Log In
Log In
Log In
Upgrade
Drug Compounding
1.04B
Log In
Log In
Log In
Log In
Upgrade
Drug Compounding Growth
10.71%
Log In
Log In
Log In
Log In
Upgrade
Other Revenue (Post-Q2 2023 Reporting)
67.00M
Log In
Log In
Log In
Log In
Upgrade
Other Revenue (Post-Q2 2023 Reporting) Growth
76.71%
Log In
Log In
Log In
Log In
Upgrade
Infusion Therapies
4.10B
Log In
Log In
Log In
Log In
Upgrade
Care & Connectivity Solutions
1.81B
Log In
Log In
Log In
Log In
Upgrade
BioPharma Solutions
-
Log In
Log In
Log In
Log In
Upgrade
BioPharma Solutions Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other Revenue (Pre-Q3 2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Other Revenue (Pre-Q3 2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other
-
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Other
-861.00M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade
Medical Products & Therapies Operating Income
950.00M
Log In
Log In
Log In
Log In
Upgrade
Medical Products & Therapies Operating Income Growth
-3.49%
Log In
Log In
Log In
Log In
Upgrade
Healthcare Systems & Technologies Operating Income
468.00M
Log In
Log In
Log In
Log In
Upgrade
Healthcare Systems & Technologies Operating Income Growth
12.79%
Log In
Log In
Log In
Log In
Upgrade
Pharmaceuticals Operating Income
313.00M
Log In
Log In
Log In
Log In
Upgrade
Pharmaceuticals Operating Income Growth
-23.98%
Log In
Log In
Log In
Log In
Upgrade
Kidney Care Operating Income
-
Log In
Log In
Log In
Log In
Upgrade
Other Operating Income
18.00M
Log In
Log In
Log In
Log In
Upgrade
Other Operating Income Growth
53.33%
Log In
Log In
Log In
Log In
Upgrade
Other
-861.00M
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
United States
5.85B
Log In
Log In
Log In
Log In
Upgrade
United States Growth
3.79%
Log In
Log In
Log In
Log In
Upgrade
Emerging Markets
1.35B
Log In
Log In
Log In
Log In
Upgrade
Emerging Markets Growth
-1.08%
Log In
Log In
Log In
Log In
Upgrade
Rest of World
3.44B
Log In
Log In
Log In
Log In
Upgrade
Rest of World Growth
4.36%
Log In
Log In
Log In
Log In
Upgrade
Americas
-
Log In
Log In
Log In
Log In
Upgrade
Americas Growth
-
Log In
Log In
Log In
Log In
Upgrade
EMEA
-
Log In
Log In
Log In
Log In
Upgrade
EMEA Growth
-
Log In
Log In
Log In
Log In
Upgrade
APAC
-
Log In
Log In
Log In
Log In
Upgrade
APAC Growth
-
Log In
Log In
Log In
Log In
Upgrade
Hillrom
-
Log In
Log In
Log In
Log In
Upgrade
Hillrom Growth
-
Log In
Log In
Log In
Log In
Upgrade

Other

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Americas Operating Income
-
Log In
Log In
Log In
Log In
Upgrade
Americas Operating Income Growth
-
Log In
Log In
Log In
Log In
Upgrade
EMEA Operating Income
-
Log In
Log In
Log In
Log In
Upgrade
EMEA Operating Income Growth
-
Log In
Log In
Log In
Log In
Upgrade
APAC Operating Income
-
Log In
Log In
Log In
Log In
Upgrade
APAC Operating Income Growth
-
Log In
Log In
Log In
Log In
Upgrade
Hillrom Operating Income
-
Log In
Log In
Log In
Log In
Upgrade
Hillrom Operating Income Growth
-
Log In
Log In
Log In
Log In
Upgrade